Navigation Links
Renovis Stockholders Approve Acquisition by Evotec
Date:5/1/2008

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS) announced today that its stockholders approved the adoption of the merger agreement with Evotec AG (Frankfurt Stock Exchange: EVT) at a special meeting of stockholders held today. The merger is expected to close by May 5, 2008.

In the transaction, each issued and outstanding share of Renovis common stock will be automatically converted into the right to receive 0.5271 of an American Depositary Share (ADSs) of Evotec, with each ADS representing two ordinary shares of Evotec, such that each issued and outstanding share of Renovis common stock will be exchanged for ADSs representing 1.0542 Evotec ordinary shares.

About Renovis, Inc

Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has worldwide collaboration and license agreements with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists.

Forward-Looking Statements

This communication contains certain forward-looking statements. All statements, other than statements of historical facts, regarding the likelihood and timing of the completion of the business combination transaction involving Evotec and Renovis, the conversion of Renovis shares into a right to receive Evotec shares, the anticipated benefits of such transaction and the plans and objectives of management are forward-looking statements and are based on management's current e
'/>"/>

SOURCE Renovis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. Renovis Reports Third Quarter 2007 Financial Results
3. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
4. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
6. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
7. Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec
8. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
9. Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders
10. Kyphon Stockholders Approve Merger with Medtronic
11. Paramount Stockholders Approve Acquisition of Chem Rx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... is pleased to announce that the Company will be ... 2015 to be held in London, UK ... and Mr. James Mellon , a director of ... the key programs at its subsidiaries, Portage Pharmaceuticals Ltd. ...
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... , ARMSTRONG, Iowa, Nov. 16 Art,s Way ... subsidiary, Art,s Way Scientific, Inc. - Buildings For Science - ... farrowing, nursery and finisher operations. The complex will be used ... swine production. Research projects will include trials on nutrition, physiology ...
... Nov. 16 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ... I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate ... Presented at the Molecular Targets and Cancer Therapeutics ... EORTC, the poster is titled: "Results of ...
... , SEATTLE, Nov. 16 /PRNewswire-FirstCall/ - Oncothyreon ... that the Company,s product candidate PX-866, a PI-3 kinase ... one of the Top 10 most promising oncology projects ... selection was made by an independent committee assembled by ...
Cached Biology Technology:Art's Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia 2Art's Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 4Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 2Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 3
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... high blood pressure drugs may be useful in preventing and ... people with diabetes. The study, the largest to date on ... prevent or treat the sight-threatening disease, they say. The findings ... monthly publication. Edward Feener and colleagues point out ...
... Pneumonia A group led by Dr. James ... Human Infectious Diseases Research of The Methodist Hospital Research ... Paton-Valentine leukocidin (PVL) does not affect methicillin-resistant Staphlococcus ... can be found in the March 2010 issue of ...
... -- Oak Ridge National Laboratory researchers will lead projects ... processor hours of computing time on supercomputers located at ... awards were made through the U.S. Department of Energy ... Experiment (INCITE) program. This year, the INCITE program will ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 52010 DOE INCITE projects allocated at ORNL 22010 DOE INCITE projects allocated at ORNL 32010 DOE INCITE projects allocated at ORNL 4
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
... 1.5mg of purified RNA samples., , This ... of aqueous RNA samples that have been ... phenol/chloroform, silica, oligo dT etc or other ... the necessary components for the stabilization of ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: